Search results
Results From The WOW.Com Content Network
Management of tuberculosis refers to techniques and procedures utilized for treating tuberculosis (TB), or simply a treatment plan for TB. The medical standard for active TB is a short course treatment involving a combination of isoniazid , rifampicin (also known as Rifampin), pyrazinamide , and ethambutol for the first two months.
Directly observed treatment, short-course (DOTS, also known as TB-DOTS) is the name given to the tuberculosis (TB) control strategy recommended by the World Health Organization. [1] According to WHO, "The most cost-effective way to stop the spread of TB in communities with a high incidence is by curing it.
Tuberculosis (TB), also known colloquially as the "white death", or historically as consumption, [7] is a contagious disease usually caused by Mycobacterium tuberculosis (MTB) bacteria. [1] Tuberculosis generally affects the lungs , but it can also affect other parts of the body. [ 1 ]
Isoniazid, also known as isonicotinic acid hydrazide (INH), is an antibiotic used for the treatment of tuberculosis. [4] For active tuberculosis, it is often used together with rifampicin, pyrazinamide, and either streptomycin or ethambutol. [5] For latent tuberculosis, it is often used alone. [4]
The current clinical classification system for tuberculosis (TB) is based on the pathogenesis of the disease. [1] Health care providers should comply with local laws and regulations requiring the reporting of TB. All persons with class 3 or class 5 TB should be reported promptly to the local health department. [2]
Ethionamide is an antibiotic used to treat tuberculosis. [2] Specifically it is used, along with other antituberculosis medications, to treat active multidrug-resistant tuberculosis. [2] It is no longer recommended for leprosy. [3] [2] It is taken by mouth. [2] Ethionamide has a high rate of side effects. [4]
AOL Mail welcomes Verizon customers to our safe and delightful email experience!
A 2008 study in the Tomsk oblast of Russia, reported that 14 out of 29 (48.3%) patients with XDR-TB successfully completed treatment. [16] In 2018, the WHO reported that the treatment success rate for XDR-TB was 34% for the 2015 cohort, compared to 55% for MDR/RR-TB (2015 cohort), 77% for HIV-associated TB (2016 cohort), and 82% for TB (2016 ...